PDF herunterladen
Thromb Haemost 2011; 106(01): 58-66
DOI: 10.1160/TH10-10-0634
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

von Willebrand factor abnormalities in aortic valve stenosis: Pathophysiology and impact on bleeding

Alessandra Casonato
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Sandro Sponga
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Elena Pontara
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Maria Grazia Cattini
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Cristina Basso
1   Department of Medical Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy
,
Gaetano Thiene
1   Department of Medical Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy
,
Giuseppe Cella
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Viviana Daidone
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Gino Gerosa
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Antonio Pagnan
1   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
› Institutsangaben Financial support: This work was supported by a grant from the Ministero dell’Universita’ e della Ricerca Scientifica e Tecnologica (MURST, 60%, 2006).
Weitere Informationen

Publikationsverlauf

Received: 05. Oktober 2010

Accepted after major revision: 14. März 2011

Publikationsdatum:
24. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Acquired von Willebrand syndrome (AVWS) may complicate severe aortic valve stenosis, due to a reduction in the haemostatically more efficient large von Willebrand factor (VWF) multimers. This study was designed to analyse the relevance of VWF abnormalities and haemorrhagic diathesis in severe aortic valve stenosis. Forty-one consecutive patients undergoing valve replacement were investigated: seven had minor bleeding symptoms in their recent history; 10 (24.3%) had a reduced VWF collagen binding (VWF:CB) to VWF antigen ratio, and 33 (80.5%) had a decrease in large VWF multimers. The shortage of large multimers was not associated with any accumulation of small VWF multimers (apparently ruling out any increased VWF proteolysis), nor was there any increase in VWF propeptide, which excludes a shorter VWF survival. The risk of developing VWF abnormalities was higher in patients with rheumatic valve disease than in degenerative cases (p=0.025) and in valves with <50% of residual endothelial cells (p=0.004). Bleeders differed from non-bleeders in that they had a higher mean transvalvular gradient and a more marked decrease in large VWF multimers. VWF abnormalities did not exacerbate peri-operative blood loss, however – a finding consistent with the full correction of these VWF abnormalities, seen already on the first postoperative day and persisting for up to six months after surgery. According to the data obtained in our cohort of patients VWF abnormalities are common in severe aortic stenosis, particularly in cases of rheumatic valve disease, but loss of the largest multimers does not seem to cause clinical bleeding in most patients.

Keywords

Aortic valve stenosis - von Willebrand factor - large VWF multimers - haemorrhagic diathesis - acquired von Willebrand syndrome
 

  • References

  • 1 Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med 1958; 259: 196
    CrossrefPubMedGoogle Scholar
  • 2 Greenstein AJ. Colonic vascular ectasias and aortic stenosis: coincidence or casual relationship?. Am J Sur 1986; 151: 347-351.
    CrossrefPubMedGoogle Scholar
  • 3 King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg 1987; 44: 514-516.
    CrossrefPubMedGoogle Scholar
  • 4 Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link?. Lancet 1992; 340: 35-37.
    CrossrefPubMedGoogle Scholar
  • 5 Gill JC, Wilson AD, Endres-Brooks J. et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758-761.
    PubMedGoogle Scholar
  • 6 Lyons SE, Bruck ME, Bowie EJW. et al. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-4430.
    PubMedGoogle Scholar
  • 7 Gralnick HR, Williams SB, McKeown LP. et al. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIA von Willebrand’s disease. Proc Natl Acad Sci USA 1985; 82: 5968-5972.
    CrossrefPubMedGoogle Scholar
  • 8 Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal an- giodysplasia after aortic valve replacement. Ann Intern Med 1986; 105: 54-57.
    CrossrefPubMedGoogle Scholar
  • 9 Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet 1996; 347: 689-690.
    PubMedGoogle Scholar
  • 10 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3: 1702-1709.
    CrossrefPubMedGoogle Scholar
  • 11 Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood 1981; 58: 387-392.
    PubMedGoogle Scholar
  • 12 Tsai H, Sussman II, Nagel RI. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-2179.
    PubMedGoogle Scholar
  • 13 Dong JF, Moake JL, Bernardo A. et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultralarge von Willebrand factor. J Biol Chem 2003; 278: 29633-29639.
    CrossrefPubMedGoogle Scholar
  • 14 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-782.
    CrossrefPubMedGoogle Scholar
  • 15 Furlan M, Robles R, Affolter D. et al. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7507.
    CrossrefPubMedGoogle Scholar
  • 16 Tsai HM, Sussman II, Ginsburg D. et al. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition of doxycycline and by monoclonal antibody VP-1. Blood 1997; 89: 1954-1562.
    PubMedGoogle Scholar
  • 17 Dent JA, Berkowitz SD, Ware J. et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-6310.
    CrossrefPubMedGoogle Scholar
  • 18 Pareti FI, Lattuada A, Bressi C. et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290-1295.
    CrossrefPubMedGoogle Scholar
  • 19 Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 323-325.
    CrossrefPubMedGoogle Scholar
  • 20 Vincentelli A, Susen S, Le Tourneau T. et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
    CrossrefPubMedGoogle Scholar
  • 21 Sucker C, Feindt P, Scharf RE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 1773
    CrossrefPubMedGoogle Scholar
  • 22 Bonow RO, Carabello BA, Chatterjee K. et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. Circulation 2008; 118: e523-e661.
    CrossrefPubMedGoogle Scholar
  • 23 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor Vlll/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325.
    CrossrefPubMedGoogle Scholar
  • 24 Gallinaro L, Cattini MG, Sztukowska M. et al. A shorter von Willebrand factor survival in O blood group explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-3545.
    CrossrefPubMedGoogle Scholar
  • 25 Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International Registry-diagnosis and management from online to bedside. Haemostaseologie 2004; 24: 50-55.
    PubMedGoogle Scholar
  • 26 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002; 28: 227-238.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Subramanian R, Olson LJ, Edwards WD. Surgical pathology of pure aortic stenosis: a study of 374 cases. Mayo Clinic Proc 1984; 59: 683-690.
    CrossrefPubMedGoogle Scholar
  • 28 Panzer S, Eslam R, Schneller A. et al. Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis. Thromb Haemost 2010; 103: 408-414.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. The Working Party on von Willebrand disease classification. J Thromb Haemost 2006; 4: 2103-2114.
    CrossrefPubMedGoogle Scholar
  • 30 Haberichter SL, Balistreri M, Christopherson P. et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-3351.
    CrossrefPubMedGoogle Scholar
  • 31 Sztukowska M, Gallinaro L Cattini. et al. Von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Brit J Haematol 2008; 143: 107-114.
    CrossrefPubMedGoogle Scholar
  • 32 Hall TS, Brevetti GR, Skoultchi AJ. et al. Re-exploration for hemorrhage following open heart surgery differentiation on the causes of bleeding and the impact on patient outcomes. Am Thorac Cardiovasc Surg 2001; 7: 352-357.
    PubMedGoogle Scholar
  • 33 Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost 2004; 2: 1720-1723.
    CrossrefPubMedGoogle Scholar
  • 34 Warketin TE, Moore JC, Morgan DG. Gastrointestinal angiodysplasia and aortic stenosis. N Engl J Med 2002; 347: 858-859.
    CrossrefPubMedGoogle Scholar